Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Esther
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation	Terminated	3	130	US	AB-205, E-CEL cells, Placebo	Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)	Hodgkin Lymphoma, Non Hodgkin Lymphoma	12/23	01/25
HIBISCUS, NCT04624659 / 2020-003884-25: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease	Recruiting	2/3	344	Europe, Canada, US, RoW	Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets	Forma Therapeutics, Inc., Novo Nordisk A/S	Sickle Cell Disease	03/26	04/27
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer	Recruiting	2	70	US	Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care	Criterium, Inc.	Breast Cancer	12/27	12/27
IVTXA, NCT05794321: Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy	Recruiting	2	150	US	Intravenous TXA	University of California, San Francisco	Postoperative Hematoma, Postoperative Seroma	05/25	05/25
SCAD, NCT04496687: International Spontaneous Coronary Artery Dissection () "i" Registry	Recruiting	N/A	1000	US, RoW		SCAD Alliance, PERFUSE Study Group	Spontaneous Coronary Artery Dissection	12/25	12/25